Sentiment-Signal
21,3
Stark Bearisch
Composite Score (0–100)
Insider (25%)
0
Keine Insider-Käufe
Institutionell (22,5%)
0
Keine neuen Positionen
Aktivist (12,5%)
0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)
Score-Verlauf (90 Tage)
Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 15.04.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | to Section 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; App |
| 07.02.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | to Section 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; App |
| 18.12.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | to Section 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; App |
| 18.03.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | the Original 8-K otherwise remains unchanged. Item 5.02 Departure of Directors or Certain Officers; Election of Director |
| 22.02.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | to Section 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; App |
| 22.01.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | to Section 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; App |
| 14.02.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | uant to Section 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Principal Officers; Election of Directo |
Stammdaten
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase 1/2a clinical trial to treat liver diseases; ARO-ENaC, which is in a Phase 1/2a clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-C3 for the treatment of complement-mediated disease that is in Phase 1/2a clinical trial; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH to treat uncontrolled gout; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase 1b clinical trial to treat clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.
Unternehmen & Branche
| Name | ARROWHEAD PHARMACEUTICALS, INC. |
|---|---|
| Ticker | ARWR |
| CIK | 0000879407 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 9,82 Mrd. USD |
| Beta | 1,27 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-Q | 264,033,000 | 30,811,000 | 0.22 | 1,604,181,000 | 568,422,000 |
| 2025-09-30 | 10-K | 829,448,000 | -1,631,000 | -0.01 | 1,385,295,000 | 466,052,000 |
| 2025-06-30 | 10-Q | 27,767,000 | -175,241,000 | -1.26 | 1,380,612,000 | 522,313,000 |
| 2025-03-31 | 10-Q | 542,709,000 | 370,445,000 | 2.75 | 1,573,498,000 | 683,321,000 |
| 2024-12-31 | 10-Q | 2,500,000 | -173,085,000 | -1.39 | 1,013,694,000 | 52,589,000 |
| 2024-09-30 | 10-K | 3,551,000 | -599,493,000 | -5.00 | 1,139,802,000 | 185,444,000 |
| 2024-06-30 | 10-Q | 0 | -170,793,000 | -1.38 | 883,759,000 | 330,547,000 |
| 2024-03-31 | 10-Q | 0 | -125,300,000 | -1.02 | 955,150,000 | 483,794,000 |
| 2023-12-31 | 10-Q | 3,551,000 | -132,864,000 | -1.24 | 626,286,000 | 160,407,000 |
| 2023-09-30 | 10-K | 240,735,000 | -205,275,000 | -1.92 | 765,552,000 | 271,343,000 |
| 2023-06-30 | 10-Q | 15,825,000 | -102,946,000 | -0.96 | 795,856,000 | 364,830,000 |
| 2023-03-31 | 10-Q | 146,267,000 | 48,675,000 | 0.45 | 891,308,000 | 446,772,000 |
| 2022-12-31 | 10-Q | 62,546,000 | -41,325,000 | -0.39 | 891,489,000 | 377,039,000 |
| 2022-09-30 | 10-K | 243,231,000 | -176,063,000 | -1.67 | 691,939,000 | 398,520,000 |
| 2022-06-30 | 10-Q | 32,412,000 | -72,046,000 | -0.68 | 751,782,000 | 453,927,000 |
| 2022-03-31 | 10-Q | 151,805,000 | 44,366,000 | 0.41 | 703,575,000 | |
| 2021-12-31 | 10-Q | 27,439,000 | -62,872,000 | -0.60 | 638,539,000 | |
| 2021-09-30 | 10-K | 138,287,000 | -140,848,000 | -1.36 | 710,148,000 | 408,822,000 |
| 2021-06-30 | 10-Q | 45,891,000 | -29,924,000 | -0.29 | 734,927,000 | |
| 2021-03-31 | 10-Q | 32,811,000 | -26,818,000 | -0.26 | 756,795,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-04-23 | Hamilton James C | Officer, Chief Medical Officer | Open Market Sale | -10,000 | 75.00 | -750,000.00 | -131,5% | |
| 2026-04-22 | Apel Daniel Joseph | Officer, Chief Financial Officer | Open Market Sale | -3,208 | 70.11 | -224,912.88 | -39,4% | |
| 2026-04-22 | Apel Daniel Joseph | Officer, Chief Financial Officer | Open Market Sale | -1,157 | 70.45 | -81,510.65 | -14,3% | |
| 2026-04-22 | Apel Daniel Joseph | Officer, Chief Financial Officer | Open Market Sale | -8,730 | 71.92 | -627,861.60 | -110,1% | |
| 2026-03-05 | Hamilton James C | Officer, Chief Medical Officer | Open Market Sale | -10,000 | 64.19 | -641,900.00 | -112,5% | |
| 2026-01-05 | Hamilton James C | Officer, Chief Medical Officer | Open Market Sale | -4,625 | 61.24 | -283,235.00 | -49,6% | |
| 2026-01-05 | Hamilton James C | Officer, Chief Medical Officer | Open Market Sale | -14,792 | 63.01 | -932,043.92 | -163,4% | |
| 2026-01-05 | O'Brien Patrick | Officer, COO | Open Market Sale | -900 | 66.01 | -59,409.00 | -10,4% | |
| 2026-01-05 | O'Brien Patrick | Officer, COO | Open Market Sale | -46 | 68.00 | -3,128.00 | -0,5% | |
| 2026-01-05 | O'Brien Patrick | Officer, COO | Open Market Sale | -313 | 68.00 | -21,284.00 | -3,7% | |
| 2026-01-05 | O'Brien Patrick | Officer, COO | Open Market Sale | -600 | 61.12 | -36,672.00 | -6,4% | |
| 2026-01-05 | Hamilton James C | Officer, Chief Medical Officer | Open Market Sale | -1,200 | 64.49 | -77,388.00 | -13,6% | |
| 2026-01-05 | Hamilton James C | Officer, Chief Medical Officer | Open Market Sale | -437 | 65.97 | -28,828.89 | -5,1% | |
| 2026-01-05 | Hamilton James C | Officer, Chief Medical Officer | Open Market Sale | -309 | 68.00 | -21,012.00 | -3,7% | |
| 2026-01-05 | O'Brien Patrick | Officer, COO | Open Market Sale | -13,451 | 62.96 | -846,874.96 | -148,4% | |
| 2026-01-05 | O'Brien Patrick | Officer, COO | Open Market Sale | -11,842 | 63.84 | -755,993.28 | -132,5% | |
| 2026-01-05 | O'Brien Patrick | Officer, COO | Open Market Sale | -6,164 | 62.23 | -383,585.72 | -67,2% | |
| 2026-01-05 | O'Brien Patrick | Officer, COO | Open Market Sale | -5,873 | 62.91 | -369,470.43 | -64,8% | |
| 2026-01-05 | O'Brien Patrick | Officer, COO | Open Market Sale | -4,368 | 61.20 | -267,321.60 | -46,9% | |
| 2026-01-05 | O'Brien Patrick | Officer, COO | Open Market Sale | -2,700 | 64.44 | -173,988.00 | -30,5% | |
| 2026-01-05 | O'Brien Patrick | Officer, COO | Open Market Sale | -2,336 | 64.04 | -149,597.44 | -26,2% | |
| 2026-01-05 | O'Brien Patrick | Officer, COO | Open Market Sale | -900 | 62.25 | -56,025.00 | -9,8% | |
| 2026-01-05 | Hamilton James C | Officer, Chief Medical Officer | Open Market Sale | -6,090 | 62.28 | -379,285.20 | -66,5% | |
| 2026-01-05 | Hamilton James C | Officer, Chief Medical Officer | Open Market Sale | -12,711 | 63.95 | -812,868.45 | -142,5% | |
| 2026-01-02 | Anzalone Christopher Richard | Director, Officer, Chief Executive Officer | Open Market Sale | -7,416 | 65.88 | -488,566.08 | -85,6% | |
| 2026-01-02 | Anzalone Christopher Richard | Director, Officer, Chief Executive Officer | Open Market Sale | -5,771 | 66.39 | -383,136.69 | -67,2% | |
| 2025-12-29 | Anzalone Christopher Richard | Director, Officer, Chief Executive Officer | Open Market Sale | -35,181 | 69.33 | -2,439,098.73 | -427,5% | |
| 2025-12-29 | Anzalone Christopher Richard | Director, Officer, Chief Executive Officer | Open Market Sale | -16,545 | 68.69 | -1,136,476.05 | -199,2% | |
| 2025-12-26 | Ferrari Mauro | Director | Open Market Sale | -7,530 | 70.00 | -527,100.00 | -92,4% | |
| 2025-12-22 | Anzalone Christopher Richard | Director, Officer, Chief Executive Officer | Open Market Sale | -2,574 | 68.85 | -177,219.90 | -31,1% | |
| 2025-12-22 | Anzalone Christopher Richard | Director, Officer, Chief Executive Officer | Open Market Sale | -10,012 | 68.33 | -684,119.96 | -119,9% | |
| 2025-12-19 | Vakiener Victoria | Director | Open Market Sale | -5,281 | 67.97 | -358,949.57 | -62,9% | |
| 2025-12-19 | Anzalone Christopher Richard | Director, Officer, Chief Executive Officer | Open Market Sale | -1,319 | 68.48 | -90,325.12 | -15,8% | |
| 2025-12-19 | Anzalone Christopher Richard | Director, Officer, Chief Executive Officer | Open Market Sale | -3,979 | 66.67 | -265,279.93 | -46,5% | |
| 2025-12-19 | Anzalone Christopher Richard | Director, Officer, Chief Executive Officer | Open Market Sale | -8,147 | 68.01 | -554,077.47 | -97,1% | |
| 2025-12-19 | Waddill William D. | Director | Open Market Sale | -500 | 68.53 | -34,265.00 | -6,0% | |
| 2025-12-19 | Waddill William D. | Director | Open Market Sale | -2,416 | 66.66 | -161,050.56 | -28,2% | |
| 2025-12-19 | Waddill William D. | Director | Open Market Sale | -5,451 | 68.01 | -370,722.51 | -65,0% | |
| 2025-12-19 | Vakiener Victoria | Director | Open Market Sale | -1,960 | 68.39 | -134,044.40 | -23,5% | |
| 2025-12-19 | Vakiener Victoria | Director | Open Market Sale | -2,799 | 66.63 | -186,497.37 | -32,7% | |
| 2025-12-19 | OLUKOTUN ADEOYE Y | Director | Open Market Sale | -827 | 68.48 | -56,632.96 | -9,9% | |
| 2025-12-19 | OLUKOTUN ADEOYE Y | Director | Open Market Sale | -3,090 | 66.70 | -206,103.00 | -36,1% | |
| 2025-12-19 | OLUKOTUN ADEOYE Y | Director | Open Market Sale | -6,083 | 68.04 | -413,887.32 | -72,5% | |
| 2025-12-17 | Anzalone Christopher Richard | Director, Officer, Chief Executive Officer | Open Market Sale | -46,287 | 63.55 | -2,941,538.85 | -515,6% | |
| 2025-12-17 | Anzalone Christopher Richard | Director, Officer, Chief Executive Officer | Open Market Sale | -35,750 | 64.51 | -2,306,232.50 | -404,2% | |
| 2025-12-17 | Anzalone Christopher Richard | Director, Officer, Chief Executive Officer | Open Market Sale | -1,981 | 66.30 | -131,340.30 | -23,0% | |
| 2025-12-17 | Anzalone Christopher Richard | Director, Officer, Chief Executive Officer | Open Market Sale | -982 | 65.53 | -64,350.46 | -11,3% | |
| 2025-12-16 | Anzalone Christopher Richard | Director, Officer, Chief Executive Officer | Open Market Sale | -8,416 | 60.51 | -509,252.16 | -89,3% | |
| 2025-12-16 | Anzalone Christopher Richard | Director, Officer, Chief Executive Officer | Open Market Sale | -6,661 | 64.29 | -428,235.69 | -75,1% | |
| 2025-12-16 | Anzalone Christopher Richard | Director, Officer, Chief Executive Officer | Open Market Sale | -3,221 | 67.87 | -218,609.27 | -38,3% | |
| 2025-12-16 | Anzalone Christopher Richard | Director, Officer, Chief Executive Officer | Open Market Sale | -1,300 | 65.77 | -85,501.00 | -15,0% | |
| 2025-12-16 | Anzalone Christopher Richard | Director, Officer, Chief Executive Officer | Open Market Sale | -166 | 66.77 | -11,083.82 | -1,9% | |
| 2025-12-16 | Anzalone Christopher Richard | Director, Officer, Chief Executive Officer | Open Market Sale | -1,000 | 64.96 | -64,960.00 | -11,4% | |
| 2025-12-16 | Anzalone Christopher Richard | Director, Officer, Chief Executive Officer | Open Market Sale | -14,095 | 62.12 | -875,581.40 | -153,5% | |
| 2025-12-16 | Anzalone Christopher Richard | Director, Officer, Chief Executive Officer | Open Market Sale | -10,963 | 61.25 | -671,483.75 | -117,7% | |
| 2025-12-16 | Anzalone Christopher Richard | Director, Officer, Chief Executive Officer | Open Market Sale | -8,476 | 62.94 | -533,479.44 | -93,5% | |
| 2025-12-15 | Anzalone Christopher Richard | Director, Officer, Chief Executive Officer | Open Market Sale | -8,147 | 69.96 | -569,964.12 | -99,9% | |
| 2025-12-15 | Anzalone Christopher Richard | Director, Officer, Chief Executive Officer | Open Market Sale | -100,532 | 68.67 | -6,903,532.44 | -1210,0% | |
| 2025-12-15 | Anzalone Christopher Richard | Director, Officer, Chief Executive Officer | Open Market Sale | -21,321 | 69.28 | -1,477,118.88 | -258,9% | |
| 2025-12-05 | PERRY MICHAEL S | Director | Open Market Sale | -16,250 | 61.03 | -991,737.50 | -173,8% | |
| 2025-11-28 | Ferrari Mauro | Director | Open Market Sale | -8,750 | 56.39 | -493,412.50 | -86,5% | |
| 2025-10-01 | Hamilton James C | Officer, Chief Medical Officer | Open Market Sale | -20,000 | 35.00 | -700,000.00 | -122,7% | |
| 2025-09-12 | Hamilton James C | Officer, Chief Medical Officer | Open Market Sale | -15,000 | 30.00 | -450,000.00 | -78,9% | |
| 2025-09-02 | Hamilton James C | Officer, Chief Medical Officer | Open Market Sale | -15,000 | 25.00 | -375,000.00 | -65,7% | |
| 2025-08-15 | Hamilton James C | Officer, Chief Medical Officer | Open Market Sale | -9,389 | 20.00 | -187,780.00 | -32,9% | |
| 2025-08-13 | Hamilton James C | Officer, Chief Medical Officer | Open Market Sale | -611 | 20.00 | -12,220.00 | -2,1% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.